Feature | July 26, 2012

CONFIRM Study Shows AF Sustained by Localized Rotors, Focuses Where to Ablate

Study shows atrial fibrillation source can be imaged and eliminated with short, targeted ablation therapy

July 26, 2012 — A new study shows promising data for a new method to image the source of atrial fibrillation (AF) and target its ablation to greatly reduce procedure time and substantially improve patient outcomes. The results of the CONFIRM (Conventional Ablation for Atrial Fibrillation With or Without Focal Impulse and Rotor Modulation) study were published online this week by the Journal of the American College of Cardiology.

The study found AF is typically caused by very few localized sources that cause disorganization in the remaining atria. Focal impulse and rotor modulation (FIRM) ablation to eliminate these sources was able to abruptly terminate or consistently slow persistent and paroxysmal AF in the vast majority of cases, and substantially improve long-term AF elimination over conventional ablation alone in this prospective case-cohort study. FIRM mapping may open the possibility for several patient-tailored therapies for AF in addition to ablation for this highly prevalent disease with major public health and societal impact. The authors concluded these results offer a novel mechanistic framework and treatment paradigm for AF.

Researchers said catheter ablation for AF is a promising therapy, but success is limited in part by uncertainty in the mechanisms that sustain AF. They developed a computational approach to map whether AF is sustained by several meandering waves or localized sources, then prospectively tested whether targeting patient-specific mechanisms revealed by mapping would improve AF ablation outcome.

The study recruited 92 subjects during 107 consecutive ablation procedures for paroxysmal or persistent (72 percent) AF. Computational AF maps were generated intraprocedurally in the FIRM-guided group, and post-procedure in the FIRM-blinded group using a novel system (RhythmView, Topera Medical, Lexington, Mass). The FIRM maps of AF revealed electrical rotors defined as sequential clockwise or counterclockwise activation contours (isochrones) around a center of rotation emanating outward to control local AF activation, or focal impulses defined by centrifugal activation contours (isochrones) from an origin. Rotors and focal impulses showed limited spatial precession and were considered AF sources only if consistent in multiple recordings over 10 minutes (equating to thousands of cycles) to eliminate transient AF patterns of unclear functional significance.

In FIRM-guided subjects, ablation commenced with FIRM to eliminate sources. Radiofrequency energy was delivered using a 3.5 mm tip irrigated catheter (Thermocool, Biosense-Webster). The catheter was maneuvered to the basket electrode overlying each source, using fluoroscopy (or digital atrial mapping), and radiofrequency energy was applied for 15 seconds to 30 seconds. The catheter was moved within the area indicated by FIRM maps to represent the center of rotation or focal impulse origin until AF terminated or ablation time at that source reached less than or equal to 10 min, whichever came first (typically less than 5 minutes per source).

For more information: http://content.onlinejacc.org/article.aspx?articleid=1221482

Related Content

News | Heart Failure| October 02, 2015
Cyberonics Inc. announced results from the extension of the ANTHEM-HF clinical study (ENCORE Study). Results of the...
Tryton Side Branch Stent, clinical trial results, Catheterization and Cardiovascular Interventions

Tryton Side Branch Stent image courtesy of Tryton Medical

News | Stents Bifurcation| October 02, 2015
October 2, 2015 — Tryton Medical Inc.
AtriCure, cryoFORM cryoablation probe, launch
Technology | Ablation Systems| October 02, 2015
AtriCure Inc. launched the cryoFORM cryoablation probe, which offers increased probe flexibility to adapt to a variety...
Intact Vascular, TOBA II study, Tack Endovascular System

Image courtesy of Intact Vascular

News | Peripheral Arterial Disease (PAD)| October 01, 2015
Intact Vascular Inc. announced the U.S. Food and Drug Administration has granted conditional approval for a U.S. and...
Johns Hopkins, sticky gel, stem cells, rat hearts, heart attacks

Hydrogel applied to beating rat hearts improves stem cell uptake by the heart muscle and speeds up tissue healing after heart attack. Image courtesy of Johns Hopkins Medicine.

News | Stem Cell Therapies| September 29, 2015
A sticky, protein-rich gel created by Johns Hopkins researchers appears to help stem cells stay on or in rat hearts and...
News | Cath Lab| September 29, 2015
The Innovation Institute announced that Boston Scientific has signed an agreement to become the founding medical device...
Eluvia drug-eluting vascular stent system, 12-month primary patency, Boston Scientific, MAJESTIC trial, CIRSE

Image courtesy of Boston Scientific

News | Stents Peripheral| September 28, 2015
New 12-month clinical trial outcomes assessing the safety and performance of the Boston Scientific Eluvia drug-eluting...
predicting arrhythmias, mcgill university, alternans patterns
News | EP Lab| September 28, 2015
Researchers have discovered how to predict some cardiac arrhythmias several steps before they even occur. It’s a...
News | Antiplatelet and Anticoagulation Therapies| September 25, 2015
The Icahn School of Medicine at Mount Sinai has launched the international TWILIGHT clinical trial to test the safety...
Medisafe, medication management, mHealth platform, blood pressure study, hypertension, adherence
News | Hypertension| September 25, 2015
Medisafe, an mHealth platform for medication management, announced the results of its blood pressure study, which...
Overlay Init